Synvect, a San Diego, CA-based biotechnology startup developing vector control solutions, raised $3M in Seed funding.
Backers included Bill & Melinda Gates Foundation, Antler, NuFund, and Redbud.
The company intends to use the funds to accelerate the development and deployment of its CRISPR-based technology, offering an eco-friendly solution to suppress disease-carrying mosquito populations.
Led by CEO Dr. Nikolay Kandul, Synvect is a biotechnology startup committed to eliminating vector-borne diseases through scalable, precision-driven mosquito suppression technology. Building on 15 years of research and $20M in prior funding, Synvect uses CRISPR to produce sterile male mosquitoes, which, when released, mate with wild females—who only mate once—preventing reproduction.
Synvect has received U.S. Environmental Protection Agency (EPA) approval for its first product, SEPARATOR, paving the way for commercial deployment. The company is launching pilot programs with government and mosquito control agencies in Florida, Texas, California, and other high-risk regions.
FinSMEs
11/03/2025